Unimark Remedies Limited, a active public limited company, was established on 01 December 1993 in Mumbai, Maharashtra, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: U23200MH1993PLC075373. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹57.01 Cr and a paid-up capital of ₹10.00 Cr.
Formerly known as Unimark Remedies Private Limited. It upholds a compliant status. Employing 4 professional, Its leadership includes Jitesh Khokhani Rameshchandra (Director), Ketan Bhupendrabhai Parikh (Additional Director), Kamlesh Rameshchandra Khokhani (Cfo). Past directors included Shekhar Ramchandra Shanbhag, Om Dutt Tyagi, Sanjeev Anant Gupte. It holds ₹1,105.65 Cr open charges and ₹344.73 Cr settled loans. Its latest AGM occurred on 29 December 2018, with the balance sheet filed on 31 March 2018. It is based at Plot -83C, Ground Floor, Motor Cycle Building, Laxminarsingh, Papan Marg, Off. Dr. E Moses Road, Gandhi Nagar, Worli, Mumbai, Maharashtra, 400018.
U23200MH1993PLC075373
075373
01 December 1993
₹57.01 Cr
₹10.00 Cr
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Unimark Remedies Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jitesh Khokhani Rameshchandra | Director | 26 May 2023 | Current |
| Ketan Bhupendrabhai Parikh | Additional Director | 27 May 2023 | Current |
| Kamlesh Rameshchandra Khokhani | Cfo | 06 Sep 2024 | Current |
| Sonalika Sushant Shrivastav | Additional Director | 06 Sep 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 29 Sep 2011 | Past |
| Pramod Abcsdd | Whole-Time Director | 17 Oct 2016 | Past |
| Pramod Abcsdd | Director | 13 Feb 2014 | Past |
| Pramod Abcsdd | Director | 31 May 2013 | Past |
| Pramod Abcsdd | Director | 31 Mar 2008 | Past |
| Pramod Abcsdd | Cfo(Kmp) | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Unimark Remedies Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 30.01% decrease. The company also saw a substantial improvement in profitability, with a 38.94% increase in profit. The company's net worth observed a substantial decline by a decrease of 30.94%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2018, Unimark Remedies had a promoter holding of 18.08% and a public holding of 81.92%. The company had 2 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹11,056,450,266.00
₹3,447,303,686.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Sep 2025 | Others | ₹35.00 Cr | Open |
| 30 Jul 2024 | Others | ₹50.00 Cr | Open |
| 03 Jun 2014 | Idbi Trusteeship Services Limited | ₹913.75 Cr | Open |
| 06 Mar 2013 | Others | ₹1.80 Cr | Open |
| 06 Mar 2013 | Others | ₹4.90 M | Open |
Explore comprehensive loan charge details -
Unimark Remedies has a workforce of 4 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Unimark Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unimark Remedies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge with Others amounted to Rs. 35.00 Cr with Charge ID 101158384 was registered on 02 Sep 2025. was documented.
The activity Kamlesh Rameshchandra Khokhani was appointed as a Cfo was appointed as a Cfo on 16 Aug 2025 & has been associated with this company since 4 months 1 day . was completed.
Progress on A charge registered on 22 Sep 2009 via Charge ID 10176412 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 06 Aug 2025. was documented.
The activity A charge registered on 27 May 2008 via Charge ID 10141701 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 06 Aug 2025. was completed.
Progress on A charge registered on 02 Apr 2007 via Charge ID 10050722 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 06 Aug 2025. was documented.
A charge registered on 02 Apr 2007 via Charge ID 10049603 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 06 Aug 2025. was recorded as a recent event.
When company bankrupt, Intas Pharmaceuticals-Shamrock Pharmachemi consortium buy Unimark Remedies with Arcil. NCLT approve plan for defunct drug maker with Rs 250 crore offer. ICICI Bank filed plea in 2018 for Rs 150 crore dues. Tribunal appoint Amit Gupta as resolution professional. Consortium's proposal approved by 72% creditors. Second big pharma acquisition through bankruptcy process. Unimark Remedies has 2 plants in Gujarat. 6,199 companies in bankruptcy, 611 have approved plans..
The USFDA says inspectors found significant deviations from standard manufacturing practices at Unimark Remedies' plants in Ahmedabad.
The CIN of Unimark Remedies Limited is U23200MH1993PLC075373.
Unimark Remedies Limited is headquartered at Plot -83C, Ground Floor, Motor Cycle Building, Laxminarsingh, Papan Marg, Off. Dr. E Moses Road, Gandhi Nagar, Worli, Mumbai, Maharashtra, 400018.
Unimark Remedies Limited was incorporated on 01 December 1993.
The current directors of Unimark Remedies Limited are
The primary industry of Unimark Remedies Limited is Manufacturing.
Unimark Remedies Limited is unlisted.
The authorized capital of Unimark Remedies Limited is ₹57.01 Cr, and the paid-up capital is ₹10.00 Cr.
The compliance status of Unimark Remedies Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX